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Abstract
Objective:  To  compare  multiple  doses  of  insulin  and  continuous  insulin  infusion  therapy  as
treatment for  type  1  diabetes  mellitus.
Methods:  40  patients  with  type  1  diabetes  mellitus  (21  female)  with  ages  between  10  and  20
years (mean=14.2)  and  mean  duration  of  diabetes  of  7  years  used  multiple  doses  of  insulin  for
at least  6  months  and  after  that,  continuous  insulin  infusion  therapy  for  at  least  6  months.  Each
one of  the  patients  has  used  multiple  doses  of  insulin  and  continuous  insulin  infusion  therapy.
For analysis  of  HbA1c,  mean  glycated  hemoglobin  levels  (mHbA1c)  were  obtained  during  each
treatment  period  (multiple  doses  of  insulin  and  continuous  insulin  infusion  therapy  period).
Results: Although  mHbA1c  levels  were  lower  during  continuous  insulin  infusion  therapy  the
difference  was  not  statistically  signiﬁcant.  During  multiple  doses  of  insulin,  14.2%  had  mHbA1c
values below  7.5%  vs.  35.71%  while  on  continuous  insulin  infusion  therapy;  demonstrating  better
glycemic control  with  the  use  of  continuous  insulin  infusion  therapy.  During  multiple  doses  of
insulin, 15--40  patients  have  severe  hypoglycemic  events  versus  5--40  continuous  insulin  infusion
therapy. No  episodes  of  ketoacidosis  events  were  recorded.
Conclusions:  This  is  the  ﬁrst  study  with  this  design  comparing  multiple  doses  of  insulin  and
continuous  insulin  infusion  therapy  in  Brazil  showing  no  signiﬁcant  difference  in  HbA1c;  hypo-
glycemic  events  were  less  frequent  during  continuous  insulin  infusion  therapy  than  during
multiple  doses  of  insulin  and  the  percentage  of  patients  who  achieved  a  HbA1c  less  than  7.5%
was greater  during  continuous  insulin  infusion  therapy  than  multiple  doses  of  insulin  therapy.
© 2015  Sociedade  de  Pediatria  de  São  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (https://creativecommons.org/licenses/by/4.0/).
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Insulinoterapia  contínua  versus  múltiplas  injec¸ões de  insulina  no  tratamento  da
diabetes  tipo  1:  um  estudo  longitudinal
Resumo
Objetivo:  Comparar  terapia  com  múltiplas  doses  de  insulina  e  o  sistema  de  infusão  continua  de
insulina no  tratamento  da  diabetes  melito  tipo  1.
Métodos:  40  pacientes  com  diabetes  melito  tipo  1  (21  mulheres)  com  idades  entre  10  e  20  anos
(média=14,2)  e  durac¸ão  média  do  diabetes  de  sete  anos  utilizaram  múltiplas  doses  de  insulina
durante  pelo  menos  seis  meses  e,  depois  disso,  sistema  de  infusão  continua  de  insulina  por  pelo
menos seis  meses.  Todos  os  pacientes  usaram  múltiplas  doses  de  insulina  e  sistema  de  infusão
continua  de  insulina.  Para  a  análise  de  HbA1c,  níveis  médios  de  hemoglobina  glicada  (mHbA1c)
foram obtidos  em  cada  período  de  tratamento  (múltiplas  doses  de  insulina  e  sistema  de  infusão
continua de  insulina).
Resultados:  Embora  os  níveis  de  mHbA1c  tenham  sido  menores  com  o  uso  de  sistema  de  infusão
continua  de  insulina  a  diferenc¸a  não  foi  estatisticamente  signiﬁcante.  Durante  o  uso  de  múltiplas
doses de  insulina,  14,2%  tiveram  valores  de  mHbA1c  <7,5%  vs.  35,71%  quando  usando  sistema
de infusão  continua  de  insulina;  demonstrando  melhor  controle  glicêmico  com  o  uso  de  sistema
de infusão  continua  de  insulina.  Durante  o  uso  de  múltiplas  doses  de  insulina,  15-40  pacientes
tiveram eventos  hipoglicêmicos  graves  contra  5-40  com  sistema  de  infusão  continua  de  insulina.
Não foram  registrados  episódios  de  cetoacidose.
Conclusões:  Esse  é  o  primeiro  estudo  cujo  desenho  comparou  o  uso  de  múltiplas  doses  de
insulina e  sistema  de  infusão  continua  de  insulina  no  Brasil,  não  demonstrando  nenhuma
diferenc¸a signiﬁcativa  nos  níveis  de  HbA1c.  Eventos  hipoglicêmicos  foram  menos  frequentes
com o  uso  de  sistema  de  infusão  continua  de  insulina  do  que  com  múltiplas  doses  de  insulina
e a  porcentagem  de  pacientes  que  obteve  um  HbA1c  <7,5%  foi  maior  com  sistema  de  infusão
continua de  insulina  do  que  com  múltiplas  doses  de  insulina.
© 2015  Sociedade  de  Pediatria  de  São  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este  é  um  artigo
Open Access  sob  a  licença  CC  BY  (https://creativecommons.org/licenses/by/4.0/deed.pt).
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iIntroduction
Diabetes  mellitus  (DM)  is  a  chronic  metabolic  syndrome  char-
acterized  by  intense  catabolism.  Type  1  diabetes  mellitus
(T1DM)  is  due  to  deﬁcient  insulin  secretion,  in  most  cases
after  autoimmune  destruction  of  pancreatic  beta  cells.
It  is  a  very  frequent  chronic  disease  affecting  children,1
with  incidence  increasing  all  over  the  world.2 In  this  way,
diabetic  ketoacidosis  (DKA)  and  hypoglycemia  are  acute
complications  of  T1DM  associated  with  variety  adverse
effects  and  both  can  have  fatal  effects  if  not  reversed  in
time.3
The  DCCT  study  (The  Diabetes  Control  and  Complications
Trial  Research  Group)4 demonstrated  that  intensive  insulin
therapy  with  multiple  doses  of  insulin  (MDI)  or  with  a
continuous  insulin  infusion  therapy  (CIIT)  would  be  the
best  treatment  for  T1DM.  In  spite  of  the  knowledge  about
both,  MDI5--7 and  CIIT,7 the  comparison  between  these
therapeutic  schemes,  particularly  among  children  and  ado-
lescents,  is  incipient.  Several  studies  have  suggested  that
CIIT  may  provide  better  glycemic  control,8--11 with  lower
risk  of  severe  hypoglycemia  and  a  smaller  weight  gain8
compared  to  the  MDI  therapy.  Among  these  analyses,  few
of  these  studies  have  been  conducted  on  children  and
adolescents.9,10The  aim  of  the  present  study  was  to  assess,  in  a  com-
parative  manner,  the  MDI  therapy  and  the  use  of  CIIT
regarding  metabolic  control  and  the  occurrence  of  acute
complications  of  the  disease  in  a  sample  of  children  and
l
d
Edolescents  with  T1DM  followed  up  at  a  public  hospital  in
ão  Paulo  state,  Brazil.
ethod
his  was  a  longitudinal  study  based  on  data  obtained  retro-
pectively  from  the  medical  records  of  patients  of  both  sexes
ged  5--20  years  with  a  diagnosis  of  T1DM  according  to  the
nternational  Society  for  Pediatric  and  Adolescent  Diabetes
riteria  (ISPAD,  1995).
The  patients  had  been  using  MDI  for  at  least  6  months,
nd  later  CIIT,  using  both  brands  available  in  Brazil,  also  for
t  least  6 months.  The  duration  of  diabetes  was  required  to
e  more  than  2  years.
All  patients  were  trained  to  count  carbohydrates,  to
odify  insulin  dosage  and  to  measure  capillary  glucose
evels  7--9  times  daily.  They  all  have  a  telephone  num-
er  to  make  contact  if  they  need,  and  the  consultations
ere  made  every  3  months  by  a  multi  professional
eam.
The  following  data  were  obtained:  sex,  age,  time  of  MDI
se,  time  of  CIIT  use,  mean  glycated  hemoglobin  levels
mHbA1c),  number  of  severe  hypoglycemic  events  requir-
ng  help  for  recovery,  and  number  of  DKA  episodes.  HbA1c
evels  were  measured  by  HPLC  and  it  was  the  same  method
uring  all  the  study.
The  research  protocol  was  approved  by  the  Research
thics  Committee  with  waiver  of  informed  consent.
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Table  1  Mean  glycated  hemoglobin  (mHbA1c)  values  (%)
for the  total  sample  (T),  Mean  glycated  hemoglobin  for
patients  who  were  submitted  to  at  least  1  year  of  each
treatment  (1y)  and  2  years  of  each  treatment  (2y).
mHbA1c  (n=40)  Mean±SD  Median  p-valuea
MDI  (T)  9.1±2.0  8.6  0.55b
CIIT  (T)  8.9±2.5  8.2
MDI (1  y)  9.3±2.3  8.6  0.095c
CIIT  (1  y) 8.4±1.9  7.8
MDI (2  y) 8.4±0.9 8.4 0.67d
CIIT  (2  y) 8.4±2.3 7.7
SD, standard deviation; MDI, multiple doses of insulin; CIIT, con-
tinuous insulin infusion therapy.
a Single-sample nonparametric Wilcoxon test.
b Comparison between MDI and CIIT.
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Table  2  Mean  glycated  hemoglobin  (mHbA1c)  values  (%)
for patients  with  levels  of  less  than  7.5%  during  only  one  of
the treatments.
Patient  mHbA1c  during  MDI  mHbA1c  during  CIIT
1  7.85 7.1
2  7.96  7.33
3 7.9  6.87
4 9.45  7.26
5 8.33  7.26
6 8.4  5.35
7 8.61  7.5
8 9.3  7.05
9 7.1  7.5
10 7.06  7.7
11 7.1  7.8
12 7.1  7.5
mHba1c, mean glycated hemoglobin for each patients; MDI, mul-
tiple daily insulin injections; CIIT, continuous insulin infusion
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hc Comparison between MDI and CIIT (1y).
d Comparison between MDI and CIIT (2y).
Data  are  reported  as  mean  (±SD)  and  median.  The  non-
arametric  Wilcoxon  test  was  used  for  the  paired  values  of
he  variables,  with  the  level  of  signiﬁcance  set  at  p<0.05.
esults
e  analyzed  the  medical  records  of  40  patients,  46.4%  of
hem  males,  who  ﬁrst  used  MDI  and  later  CIIT  during  the
eriod  from  2011  to  2012.  At  the  time  of  data  collection,
atient’s  age  ranged  from  10  years  and  eight  months  to
0  years  and  2  months  (mean±standard  deviation:  14±2.35
ears).  Time  since  the  diagnosis  of  the  disease  ranged  from
 years  and  2  months  to  15  years  and  3  months  (mean  7.0
ears).
Time  of  MDI  ranged  from  8  months  to  14  years  and  9
onths  (mean±standard  deviation:  5.1±3.6  months).  Time
f  CIIT  use  ranged  from  6  months  to  4  years  and  5  months
mean±standard  deviation:  1.4±3.6  years)  (Table  1).
The  data  did  not  show  variation  according  to  sex.
For  analysis  of  HbA1c  levels,  the  results  obtained  during
ach  treatment  period  (MDI  and  CIIT)  were  retrieved  and
he  mHbA1c  value  was  calculated  for  each  patient  and  each
eriod.  The  mean  and  the  median  mHbA1c  values  were  then
alculated  for  the  sample  and  for  the  period  of  each  treat-
ent.  Table  2  shows  the  mHbA1c  results  obtained  in  the  two
eriods.  The  data  show  that,  although  mHbA1c  levels  were
ower  during  the  use  of  CIIT  than  during  the  use  of  MDI,  no
igniﬁcant  difference  was  observed.
Analysis  of  the  data  for  patients  who  had  used  at  least
ne  year  of  each  treatment  revealed  that  mHbA1c  lev-
ls  were  9.3  (±2.3)%  during  the  MDI  period  (median:  8.6),
nd  8.4  (±1.9)%  during  the  CIIT  period,  with  a  median  of
.8%  (p=0.095),  showing  that  there  was  no  signiﬁcant  differ-
nce  in  mHbA1c  levels  obtained  during  the  two  treatments
Table  1).
Analysis  of  the  data  for  patients  who  had  used  at  least
wo  years  of  each  treatment  revealed  that  mHbA1c  levels
ere  8.4  (±0.9%)  during  the  MDI  period,  with  a  median  of
.4,  and  8.4  (±2.3%)  with  a  median  of  7.7%  during  the  period
f  use  of  CIIT.  Again,  the  Wilcoxon  test  showed  no  signiﬁcant
ifference  between  periods  (p=0.67)  (Table  1).
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During  the  use  of  MDI,  14.2%  had  mHbA1c  values
elow  7.5%,  the  value  recommended  by  ISPAD  as  target  to
etabolic  control,  and  during  the  use  of  CIIT  35.71%  had
HbA1c  values  below  7.5%,  demonstrating  better  glycemic
ontrol  with  the  use  of  an  infusion  pump  for  treatment.
Analysis  of  cases  with  less  than  7.5%  of  mHbA1c  levels  in
nly  one  of  the  treatments  (MDI  or  CIIT)  revealed  that  eight
f  the  12  patients  (66.6%)  showed  reduced  mHbA1c  lev-
ls  when  they  switched  to  CIIT,  while  four  patients  (33.3%)
howed  lower  mHbA1c  levels  during  treatment  with  MDI
Table  2).
Regarding  acute  complications,  the  number  of  hos-
italizations  and  visits  to  emergency  services  due  to
ypoglycemic  and  diabetic  ketoacidosis  events  were
ecorded  during  the  two  treatment  periods.
During  MDI,  15--40  patients  have  hypoglycemic  events
eeding  help  from  other  person.  From  those  15  patients,  3
ad  two  events,  1  tree  events  and  one,  4  events.  No  ketoaci-
osis  events  were  recorded.
During  CIIT,  5--40  patients  have  hypoglycemic  events
eeding  help  from  other  person.  From  those  5,  only  one
vent  by  each  one  was  recorded.  Again,  no  ketoacidosis
vents  were  recorded.
Analysis  of  the  mean  number  of  events  showed  that  more
omplications  occurred  during  MDI  treatment  than  during
IIT  (p=0.021,  single-sample  nonparametric  Wilcoxon  test).
iscussion
bA1c  level  is  the  most  useful  measure  for  the  evaluation
f  metabolic  control  and  the  only  one  demonstrating  good
orrelation  with  vascular  complications.12--14 The  process  of
emoglobin  glycation  involves  a  permanent  bond  with  reduc-
ng  sugars  such  as  glucose  and,  because  of  this  irreversible
ond,  HbA1c  values  correspond  to  the  hyperglycemia  levels
f  DM  patients  in  a  more  reliable  and  true  manner  than  the
asting  glycemic  levels.
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The  DCCT  study  demonstrated  that,  when  HbA1c  exceeds
7.5%,  the  risk  of  complications  increases  signiﬁcantly.12--14
The  ISPAD15 recommends  a  value  of  HbA1c  of  less  that  7.5%.
The  present  study  showed  that  14.2%  of  the  patients
had  lower  than  7.5%  mHbA1c  during  the  use  of  MDI,  while
35.71%  showed  an  mHbA1c  value  lower  than  7.5%  with  the
use  of  CIIT,  demonstrating  better  glycemic  control  with  the
use  of  infusion  pump  therapy.  The  same  conclusion  was
observed  when  individual  analysis  cases  of  patients  with
mHbA1c  lower  than  7.6%  in  at  least  one  of  the  treatments
(Table  2).
Comparison  of  the  periods  of  use  of  MDI  and  CIIT
revealed  a  reduction  of  both  the  mean  (9.1--8.9)  and  the
median  (8.6--8.2)  values  of  HbA1c  levels;  although  these
values  no  signiﬁcant  difference  was  observed.  Several  stud-
ies,  especially  those  conducted  on  young  individuals,  have
demonstrated  that  CIIT  and  MDI  induce  similar  results  of
glycemic  control.16--19 In  a  recent  meta-analysis,  Yeh  et  al.16
analyzed  33  randomized  and  controlled  studies  comparing
the  two  therapies  in  children  and  adults  with  T1DM  and
concluded  that  most  studies  showed  similar  effects  on  the
control  of  glycemia  in  children,  with  a  favorable  effect  of
the  use  of  CIIT  on  the  reduction  of  HbA1c  levels  in  adults.
However,  other  studies  have  shown  that  the  use  of  CIIT  pro-
motes  a  reduction  of  HbA1c  levels  both  in  children20--24 and
in  adults.21,22,24
In  view  that  the  time  of  use  of  one  of  the  therapies  might
inﬂuence  the  evaluation  of  HbA1c  levels,  the  same  analy-
sis  of  mean  and  median  HbA1c  values  were  performed  in
patients  with  at  least  1  year  of  each  treatment.  Another
analysis  was  performed  in  patients  with  at  least  2  years  of
each  treatment  (Table  1).  However,  no  signiﬁcant  difference
was  detected  favoring  one  of  the  treatments.
Regarding  adverse  effects,  a  systematic  review  by  Pickup
et  al.25 showed  that  the  frequency  of  severe  hypoglycemia
episodes  was  reduced  4.2  times  with  the  use  of  CIIT,
compared  to  MDI,  although  other  studies  did  not  detect
a  signiﬁcant  difference  in  the  number  of  adverse  events
between  the  two  treatments.20--22,26 In  the  present  patient
series,  there  was  a  reduction  of  the  frequency  of  severe
hyperglycemic  episodes.  Similarly  to  our  data,  a  previous
Brazilian  study  has  also  showed  reduction  of  severe  hypo-
glycemia  episodes.  In  spite  of  fewer  subjects  and  shorter
period  of  observation,  this  analysis  showed  a  little  improve-
ment  of  metabolic  control;  furthermore,  the  authors  have
not  compared  MDI  and  CITT.27 A  recent  paper  showed  in  345
patients  a  0.6%  reduction  of  HbA1c  levels  from  injections  to
insulin  pump  therapy.  The  authors  also  showed  a  reduction
of  severe  hypoglycemic  events  and  DKA  episodes.28
In  the  design  of  the  present  study,  the  fact  that  each
patient  acted  as  his  own  control  eliminated  inter  individual
differences  (such  as  eating  habits,  patterns  of  physical  activ-
ities,  motivation  and  attitude  toward  the  disease,  among
others)  that  might  interfere  with  the  analysis  since  two  sam-
ples,  even  when  matched,  may  show  differences.  However,
a  limitation  of  the  study  is  the  fact  that  it  was  not  con-
trolled,  with  a  retrospective  and  with  small  sample.  Other
important  issue  is  the  period  of  observation;  probably  longer
periods  of  time  could  have  shown  a  signiﬁcant  difference  in
the  metabolic  control.  Despite  these  limitations,  to  the  best
of  our  knowledge,  this  is  the  ﬁrst  study  with  this  design  com-
paring  the  use  of  two  forms  of  basal-bolus  therapy  for  the
189
etabolic  control  of  diabetes  and  of  the  occurrence  of  acute
omplications  of  the  disease,  in  Brazil.
In  conclusion,  intensive  insulin  therapy  (MDI  or  CIIT)
epresents  the  best  form  of  treatment  in  order  to  obtain
dequate  metabolic  control  for  T1DM  patients.  Analysis  of
everal  studies  showed  that  there  is  no  consensus  about  the
hoice  between  MDI  and  CIIT  for  the  treatment  of  T1DM,
egarding  glycemic  control  and  the  rates  of  adverse  events.
he  present  study  is  the  ﬁrst  in  Brazil  to  compare  the  two
orms  of  therapy  with  a  design  of  patient  as  self-control,
howing  improvement  in  metabolic  control  with  the  use  of
IIT,  with  a  reduced  occurrence  of  acute  complications  of
iabetes  in  this  sample.
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